Advertisement
Research Topics
Subscribe to Research Topics
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

99% of Alzheimer's Drug Trials Fail, Study Says

July 7, 2014 1:53 pm | News | Comments

Researchers have conducted the first-ever analysis of clinical trials for Alzheimer’s disease (AD), revealing an urgent need to increase the number of agents entering the AD drug development pipeline and progressing successfully towards new therapy treatments. Read more...

Chronic Pain Drug Pushes Through Phase 3

July 7, 2014 12:47 pm | News | Comments

Endo Pharmaceuticals Inc. and BioDelivery Sciences International Inc. announced positive top-line results from its pivotal Phase 3 efficacy study of BEMA buprenorphine in opioid-experienced patients. Read more...            

Diabetes Drug Receives MMA in Japan

July 7, 2014 11:23 am | News | Comments

Mitsubishi Tanabe Pharma Corp. and Daiichi Sankyo Co. Ltd., announced that Mitsubishi Tanabe Pharma has received approval to manufacture and market the SGLT2 inhibitor, Canaglu tablets (canagliflozin hydrate) 100 mg in Japan, for the treatment of patients with type 2 diabetes mellitus. Read more...

Advertisement

BioDelivery’s Pain Drug Better than Placebo, Stocks Soar

July 7, 2014 11:17 am | News | Comments

Shares of BioDelivery Sciences International - a Raleigh, North Carolina, company - surged Monday before markets opened and after the drug developer said its potential severe pain treatment fared better than a placebo, or fake drug, in another late-stage study. Read more...

Japan First to Approve Alectinib for ALK+ NSCLC

July 7, 2014 11:11 am | News | Comments

Roche announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved alectinib for the treatment of people living with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase fusion gene-positive (ALK+). Read more...

Pseudogenes May Help in the Discovery of Biomarkers

July 7, 2014 11:06 am | News | Comments

Alas, the thankless pseudogene: dysfunctional, unloved and seemingly of little use, these poor-cousin relatives of genes have lost their protein-coding abilities, contain material not essential for an organism’s survival and are the “last stop” for removal of genomic waste. Read more...

MRC Technology, AstraZeneca Renew Drug Target Collaboration

July 7, 2014 10:57 am | News | Comments

MRC Technology and AstraZeneca announced the renewal of their strategic collaboration which focuses on the identification and selection of novel drug targets with the potential to become potent and selective therapeutics for the treatment of serious disease in the areas of oncology, inflammation and diabetes. Read more...

Bioelectronics Could Lead to a New Class of Medicine

July 3, 2014 12:00 pm | News | Comments

Imagine having tiny electronics implanted somewhere in your body that can regulate nerve signals and make symptoms of various disorders go away. That’s the vision of the field of bioelectronic medicine— the emerging discipline that has made enough promising advances to draw a big investment by a pharmaceutical giant. Read more...

Advertisement

Insys Cannabidiol Snags Orphan Designation for Rare Epilepsy

July 3, 2014 12:00 pm | News | Comments

Insys Therapeutics Inc. announced that the FDA has granted orphan drug designation to its pharmaceutical cannabidiol (CBD) for the treatment of Dravet syndrome, a rare pediatric-onset epilepsy. Read more...             

Marrow Transplants Can Reverse Adult Sickle Cell

July 3, 2014 12:00 pm | by Lindsey Tanner, AP Medical Writer | News | Comments

Bone marrow transplants can reverse severe sickle cell disease in adults, a small study by government scientists found, echoing results seen with a similar technique used in children. Read more...               

Jazz to Acquire Rights to Defibrotide from Sigma-Tau

July 2, 2014 3:50 pm | News | Comments

Jazz Pharmaceuticals plc announced that the company has signed a definitive agreement with Sigma-Tau Pharmaceuticals Inc. under which a subsidiary of Jazz Pharmaceuticals plc will acquire from Sigma-Tau rights to defibrotide in the United States and all other countries in the Americas. Read more...

Coming Soon: A Harder-to-Abuse Zohydro

July 2, 2014 3:43 pm | News | Comments

The drugmaker Zogenix said a harder-to-abuse version of its powerful painkiller Zohydro could be reviewed by regulators this fall and, if approved, might hit the market early next year, and they are also working to develop a tablet version that maintains the medicine's extended-release properties even when it is crushed or chewed. Read more...

BI Submits MAAs in Europe for COPD Combo Drug

July 2, 2014 3:34 pm | News | Comments

Boehringer Ingelheim announced the submission of Marketing Authorization Applications in 31 European countries for the once-daily fixed-dose combination of tiotropium + olodaterol Respimat as a maintenance bronchodilator treatment for patients with chronic obstructive pulmonary disease. Read more...

Advertisement

Actavis Acquires Furiex Pharmaceuticals

July 2, 2014 3:28 pm | News | Comments

Actavis announced that its subsidiary Forest Laboratories has successfully completed its acquisition of Furiex Pharmaceuticals in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval. Read more...

Some 500 Genes Differ in Bipolar Patients’ Neurons

July 2, 2014 3:16 pm | by Cynthia Fox, Science Editor | Articles | Comments

Neurons of patients with bipolar disorder (BP) differ from the norm in a “striking” 500 or so genes, according to preliminary data generated using the Nobel-Prize-winning iPSC (induced pluripotent stem cell) approach, by Salk Institute neuroscientist Fred Gage. Read more...

Pfizer Receives Kosher Certification for Gaucher Disease Drug

July 2, 2014 10:55 am | News | Comments

Pfizer Inc. announced that the Orthodox Union has granted kosher certification to Elelyso (taliglucerase alfa) for injection, an enzyme replacement therapy for the long-term treatment of adults with a confirmed diagnosis of Type 1 Gaucher disease. Read more...

Isis Earns $1M from GSK for Advancing Hep B Program

July 2, 2014 10:49 am | News | Comments

Isis Pharmaceuticals Inc. announced that it has earned a $1 million payment from GlaxoSmithKline related to the advancement of its program to develop antisense drugs to treat hepatitis B virus, a serious health problem that can lead to significant and potentially fatal health conditions. Read more...

Common Element of Ancient Origin Controls Na, Ca Cellular Gates

July 2, 2014 10:43 am | News | Comments

Researchers at Johns Hopkins have spotted a strong family trait in two distant relatives: The channels that permit entry of sodium and calcium ions into cells - both of which are critical to life - turn out to share similar means for regulating ion intake, they say. Read more...

Lung Cancer Alliance Commends NCI for SCLC Scientific Framework

July 2, 2014 10:32 am | News | Comments

The National Cancer Institute (NCI), led by Harold Varmus, MD, presented to Congress a scientific framework that lays out important steps needed to make advances in small cell lung cancer, one of the most lethal forms of the disease. Read more...

Agenus Glioblastoma Vaccine Extends Survival in Phase 2

July 2, 2014 8:30 am | News | Comments

Agenus announced Phase 2 study results showing that patients with newly diagnosed glioblastoma multiforme who received Prophage autologous cancer vaccine, added to the standard of care treatment, lived nearly twice as long as expected. Read more...

Approach IDs Mutations as Targets for Melanoma Immunotherapy

July 2, 2014 8:30 am | News | Comments

A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy called adoptive T-cell therapy. Read more...

Sanofi Pasteur, CureVac to Develop mRNA-based Prophylactic Vaccine

July 2, 2014 8:30 am | News | Comments

CureVac and Sanofi Pasteur S.A. have executed an exclusive license agreement to develop and commercialize an mRNA-based vaccine against an undisclosed pathogen. Read more...                       

OncoGenex Opens Enrollment for Lung Cancer Trial

July 2, 2014 8:30 am | News | Comments

OncoGenex announced initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating apatorsen in previously untreated patients with advanced squamous cell lung cancer. Read more...      

Quark Completes Trial of siRNA Compound in Kidney Transplant Patients

July 2, 2014 8:30 am | News | Comments

Quark Pharmaceuticals reported completion of a randomized, placebo-controlled multicenter Phase 2 trial of QPI-1002 for the prophylaxis of delayed graft function in ESRD dialysis-dependent patients undergoing deceased donor kidney transplantation. Read more...

UMD, GBSI Partner to Advance Antibody Standards

July 1, 2014 2:22 pm | News | Comments

The University of Maryland (UMD) Fischell Department of Bioengineering and the Maryland Center for Excellence in Regulatory Science (M-CERSI) have partnered with the Global Biological Standards Institute (GBSI) to launch the Collaboration to Advance Antibody Standards. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading